September 12, 2011
We are proud to announce that Karl Swartling and Mats Carlson have joined the board of directors. Their experience and knowledge will be of significant value for the company. More information on their respective backgrounds can be found here.
May 1, 2011
It is our pleasure to welcome Peter Sellei M.D. as new CEO to NeoDynamics AB. His vast experience and professionel background in developing life science companies will enable NeoDynamics to reach its goal of providing healthcare with innovative medtech products. Peter Sellei was previously active at Investor AB and board member of several companies in the life science sector.
April 4, 2011
NeoDynamics' PRFA cancer treatment technology was featured in the Swedish science television programme "Vetenskapens Värld". The feature, about 4 minutes into the programme, is available here.
February 24, 2011
We showed that platelets facilitate metastastic growth of disseminated cancer cells in breast cancer patients. This indicates that today's diagnostic biopsy procedures, causing bleeding in association with blood vessel injury, may initiate tumour cell spread of a still local tumour disease. Our anti-seeding technology uses radiofrequency pulses to seal intratumoral blood vessels and significantly reduce bleeding. Find the study here.
February 11, 2011
A newspaper article about our projects has been published in Affärstidningen Näringsliv. Its online version can be found here. The article appears on page 31.
February 7, 2011
We are proud to announce that NeoDynamics has been named one of the 20 most innovative companies in Sweden by the Swedish Institute. Our projects will thus be displayed in an exhibition touring globally starting autumn 2011 in Silicon Valley, USA. See here.
February 3, 2011
Our anti-seeding technology is featured as a Research Highlight in Nature Review Clinical Oncology and can be found here
December 7, 2010
Our latest article on the anti-seeding technology has made the top ten in the British Journal of Cancer.
November 30, 2010
Our projects have recieved a grant from the Swedish Breast Cancer Association (BRO) as well as from the Capio Research Foundation (Forskningstiftelse) via S:t Görans Hospital.
November 22, 2010
Patient number 13 and 14 of the ongoing study have undergone PRFA treatment at St. Görans Hospital today.
November 19, 2010
A breast cancer patient who decided against surgery and instead received PRFA treatment two month ago has visited St. Görans Hospital for a follow-up today. MRI pictures show a complete destruction of the tumor. The case is being prepared for publication.
November 11, 2010
Media coverage of our activities can now be found here.
November 3, 2010
A clinical study on our anti-seeding technology has today been published in the British Journal of Cancer and can be found here.
Furthermore patient 10 and 11 of the ongoing study have undergone PRFA treatment on an outpatient basis at St. Görans Hospital today.
October 11, 2010
Two patients have undergone PRFA treatment on an outpatient basis today. They constitute patient number 8 and 9 of the ongoing PRFA study which is now being prepared for publication.
October 7, 2010
Today we have received ethical approval for a study on the treatment of benign breast disease (fibroadenoma) with PRFA.
September 29, 2010
An article on our anti-seeding technology has been accepted for publication by a high quality peer-reviewed scientific journal.
July 16, 2010
Hardware development of the new PRFA treatment device N-2000 was finalized today.
July 1, 2010
Development on a core needle biopsy (CNB) device encorporating the anti-seeding technology has been initiated.
June 9, 2010
We have commenced the study on the realationship between diagnostic needle procedures and circulating tumor cells (CTC). The first patient underwent core needle biopsy at St. Görans Hospital today.
February 19, 2010
The article published on our first PRFA study is now avaliable here.
Frebruary 17, 2010
We have today recieved an ethical permit for analyzing the relationship between circulating tumor cells (CTC) in peripheral blood and diagnostic needle biopsies.
January 22, 2010
Our study on PRFA entitled "Feasibility study on the treatment of small breast carcinoma using percutaneous US-guided preferential radiofrequency ablation (PRFA)" was today accepted for publication in "The Breast".
October 29, 2009
Today patient number 25 has undergone a diagnostic procedure at St. Görans Hospital using the anti-seeding technique.
October 28, 2009
For the first time a PRFA treatment was carried out at the Department of Mammography at St. Görans Hospital today. This constitues a substantial leap forward towards outpatient-based treatment of breast lesions. Pictures of the treatment procedure can be found here.
October 9, 2009
An interview with Kai-Uwe Schässburger for the magazine of the Swedish Association of Scientists can be found here
October 5, 2009
Patient number four was successfully treated with PRFA at St. Görans Hospital today.
September 30, 2009
Patient number three was sucessfully treated with PRFA at St. Görans Hospital today.
September 29, 2009
Ph.D. Student Kai-Uwe Schässburger gave a presentation on our research activities at the Swedish Medical Technology Days in Västerås today. The abstract can be found here.
September 23, 2009
Our newly developed needle for fine needle aspiration (FNA) was tested under US-guidance at St. Görans Hospital today. Images and more information can be found here.
June 23, 2009
The second patient of the ongoing PRFA study has been successfully treated and operated. MRI pictures showing the lesion before and one week after treatment can be viewed here.
June 1, 2009
We are glad to welcome Pär Nordström as new CEO for NeoDynamics. Pär has many years of experience in product development, marketing and sales in the field of medical technology. He was previously marketing director at Elekta AB. Read the press release here.
May 26, 2009
The first treated patient of our current PRFA study has successfully undergone breast-conserving surgery at St. Görans Hospital today. Pathological analysis showed no viable cancer cells.
May 4, 2009
The first patient of our current PRFA study has been successfully treated at St. Görans Hospital today. In three weeks the treated breast tumour will be resected and examined.
April 2, 2009
Ultrasound pictures documenting our unique anti-seeding procedure applied in the AntiMeta™ project can now be viewed here.
February 17, 2009
The final 2 patients of the first PRFA study have undergone treatment at St. Görans Hospital today. Results of the study involving the treatment of 31 patients in total will be published shortly.
February 6, 2009
We are glad to welcome Kai-Uwe Schässburger to our team. As an industrial Ph.D. student in collaboration with Karolinska Institutet he will drive forward research at NeoDynamics.
February 3, 2009
Karolinska Development AB has decided to become a shareholder of NeoDynamics AB by investing 5 Mio. SEK
"It is a great pleasure for us to welcome Karolinska Development as a shareholder of NeoDynamics. With their great knowledge of the life science industry they will be a valuable partner for further development."
Claes Stenlander, CEO NeoDynamics
January 29, 2009
AntiMeta™ has been successfully registered as a EU trademark. The certificate is viewable here.
January 14, 2009
The first patients of the current AntiMeta™ study have been diagnosed at St. Görans Hospital using the anti-seeding technique.